Vivimed Labs Peer Comparison

NSE: VIVIMEDLAB | BSE: 532660

₹6.94

₹0.13 (1.91%)

As on 27-Aug-2026IST

Market cap

₹58 Cr

Revenue (TTM)

₹70 Cr

P/E Ratio

P/B Ratio

-0.2

Div. Yield

0 %

Edit

	Vivimed Labs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	58	31,878	30,554	28,624	27,296
Revenue (₹ Cr)	70	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-176.47	414.00	288.22	-371.81	387.35
Net Margin (%)	-231.21	11.23	14.79	-3.93	26.01
RoE (%)	--	8.38	29.77	-3.85	25.18
Price to Earnings	--	77.94	106.01	--	70.67
Price-To-Book	-0.23	6.33	22.76	3.58	15.79

Income Statement (₹ Cr)

	Vivimed Labs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	69.99	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	76.33	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	222.43	2,792.00	1,485.56	8,195.15	919.25
EBITDA	-152.44	772.00	450.24	1,010.13	542.56
Depreciation	26.05	226.00	50.83	857.51	37.68
EBIT	-178.49	546.00	399.41	152.62	504.88
Interest	4.18	217.00	40.84	342.73	3.77
Other Income	6.34	122.00	12.78	244.31	27.45
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	-176.33	463.00	371.35	-162.68	528.56
Provision for Tax	0.14	49.00	83.14	209.13	141.21
Profit after Tax	-176.47	414.00	288.22	-371.81	387.35

	Vivimed Labs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	-210.55	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	515.92	1,712.00	202.03	5,044.14	42.40
Current Liabilities	448.11	1,622.00	835.87	4,758.28	230.82
Total Liabilities	920.85	8,100.00	1,451.43	15,513.53	1,549.26

	Vivimed Labs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	583.95	5,343.00	519.60	10,211.52	1,026.85
Current Assets	168.00	2,606.00	1,681.81	7,191.66	881.27
Total Assets	920.85	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	376.33	1,859.00	393.17	4,720.27	8.18
Net Current Assets	-280.11	984.00	845.94	2,433.38	650.46
Contingent Liabilities	182.90	770.26	12.25	99.76	15.38

	Vivimed Labs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-1.75	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-4.53	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	4.96	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	-1.32	-396.00	54.56	-25.99	155.52

	Vivimed Labs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-9.07	4.07	26.97	6.61	20.14
ROE (%)	0.00	8.38	29.77	-3.85	25.18
ROA (%)	-21.08	4.94	24.77	-2.21	21.93
EBIT Margin (%)	-255.02	15.32	20.63	1.66	34.54
Net Margin (%)	-231.21	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Vivimed Labs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-39.80	18.37	46.65	0.78	40.90
EBIT Growth (%)	-436.45	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	-452.15	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	-452.15	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	-68.36	29.77	42.49	2.28	94.96

	Vivimed Labs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	-0.33	79.96	104.15	-91.09	70.69
Price / Book Value	-0.23	6.33	22.71	3.56	15.80
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.08
EV/EBITDA	-2.84	43.17	67.52	32.32	49.88
Market Cap (₹ Cr)	0.00	23,064.69	0.00	29,731.27	19,988.69

	Vivimed Labs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	-0.34	0.31	0.11	0.53	0.01
Short term debt to equity ratio	-8.89	0.11	0.54	0.12	0.02
Current Ratio	0.37	1.61	2.01	1.51	3.82
Quick Ratio	0.35	1.06	1.14	0.87	2.82
Interest Coverage	-41.16	3.13	10.09	0.53	141.16

	Vivimed Labs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	64.77	16.50	26.28	23.44	24.80
Asset Turnover	0.08	0.43	1.66	0.55	0.83
Receivable days	246.32	60.36	47.59	77.05	90.06
Inventory Days	192.78	64.42	62.58	77.13	61.02
Payable days	254.58	218.94	228.78	173.49	96.06
Cash Conversion Cycle	184.52	-94.15	-118.62	-19.30	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.